retatrutide phase 2 trial obesity nejm 2023 of for Retatrutide Phase 3: TRIUMPH Program

Our findings demonstrate their metabolic stability and selective agonism at Y1-R, Y2-R, and GLP-1R that lead to stimulation of insulin secretion from pancreatic islets and muscle glucose uptake in vitro and profound reductions in food intake and body weight in experiments performed in vivo

A 10 mg vial provides roughly one week of dosing at the lower maintenance range

Most safety concerns with Retatrutide involve manageable side effects that improve with time and appropriate dose escalation

Comparing Retatrutide to Other Injectables Retatrutides injection site reaction profile compares favorably to other subcutaneous medications

Its time to follow the science and prioritize a new population health strategy

All of these drugs belong to a class of medications known as GLP-1 receptor agonists, which mimic a hormone in your body called glucagon-like peptide-1 (GLP-1)